Migraine And Headache

Positive Results for Ubrogepant in Phase 3 Migraine Trial

By February 06, 2018

A total of 1,327 migraine patients were treated in the study for a single migraine attack. At 2 hours after migraine attack, 19.2% (n=423) and 21.2% (n=448) of ubrogepant 50mg and 100mg were pain free, respectively.

Migraines and Cardiovascular Disease: What's the Link?

February 01, 2018

There were positive associations for migraine with myocardial infarction, ischemic stroke and hemorrhagic stroke, venous thromboembolism, and atrial fibrillation or flutter.

GammaCore Approved for the Acute Treatment of Migraine Pain

By January 29, 2018

The new approval for migraine patients was supported by the PRESTO trial, a multicenter, randomized, double-blind, sham-controlled trial.

Erenumab Effective in Migraine Patients With Multiple Treatment Failures

By January 23, 2018

Aimovig is a fully human monoclonal antibody, designed to selectively block the calcitonin gene-related peptide (CGRP) receptor.

Significant Migraine Risk Reduction Seen With Eptinezumab in Phase 3 Trial

By January 08, 2018

The 'PROMISE 2' study included 1,072 patients who were randomized to receive eptinezumab (300mg or 100mg), or placebo once every 12 weeks.

FDA to Review Fremanezumab for Migraine Prevention

By December 19, 2017

Results from the CM trial found that the fremanezumab arm experienced statistically significant reduction in the number of monthly headache days of at least moderate severity vs. placebo.

Successful Treatment of Migraine With Antiviral/NSAID Combo

By December 14, 2017

Previous literature has speculated on an association between migraine headache and HSV.

FDA to Review Galcanezumab for Migraine Prevention in Adults

By December 11, 2017

The application includes data from three Phase 3 trials; Evolve-1, Evolve-2 (6 months) and Regain (3 months).

ASHP: Revised Standards can Build Framework for Opioid Stewardship

December 06, 2017

The new and revised standards from The Joint Commission were published in July 2017 to address some of the issues associated with over-prescribing and lack of monitoring.

Novel Therapy Shown to Significantly Cut Monthly Migraine Days

By November 30, 2017

Migraine days were cut by ≥50% for half of the 140mg group, by 43.3% for the 70mg group, and by 26.6% for the placebo group.

Two New Migraine Treatment Devices Available

By November 29, 2017

The Food and Drug Administration (FDA) approval was based on several studies that demonstrated 1 hour of use with Cefaly Acute could relieve or stop the migraine headache.

Botox Efficacy Evaluated for Migraine in Pediatric Patients

October 24, 2017

Statistically significant changes in migraine intensity, frequency, duration from pre- to post-therapy

Could Ketamine Infusion Offer Analgesia in Migraines?

October 23, 2017

The mean length of ketamine infusion was 5.1 days, with the lowest pain rating on day 4, which was achieved at mean ketamine rates of 30.8±3.6 mg/hr less than the maximum dose.

Migraine Patch Product No Longer Available

By October 20, 2017

Zecuity, launched in September 2015, is a transdermal system that delivers a therapeutic dose via a single-use, battery-powered patch wrapped around the upper arm or thigh.

Non-Opioid Tx Beats Hydromorphone for Migraine Pain Relief in the ED

By October 19, 2017

Participants were randomized to either hydromorphone 1mg (n=64) or prochlorperazine 10mg plus diphenhydramine 25mg (n=62).

BLA Submitted for Migraine Prevention Drug Fremanezumab

By October 17, 2017

The studies looked at the safety, tolerability, and efficacy of 4 dose regimens of subcutaneous fremanezumab vs. placebo over 16 weeks.

New Type of Chronic Daily Headache Described in Case Series

By September 26, 2017

With regards to treatment, all of the patients responded to CSF pressure-/volume-lowering therapies (ie, acetazolamide or spironolactone).

FDA Clears Cefaly Device for Use During Migraine Attack

By September 21, 2017

Cefaly Acute is an external trigeminal nerve stimulator (e-TNS) approved for use under prescription.

Investigational Migraine Tx Shows Promise in Phase 3 Trial

By September 14, 2017

Results demonstrated that at 12 weeks after the first dose of fremanezumab, the CM group had reductions of monthly headaches; -4.6 days for the monthly dose, -4.3 days for the quarterly dose and -2.5 for the placebo group (P<0.0001).

Oxygen Tx for Cluster Headache 'Not Prohibitively Expensive', Study Says

By September 14, 2017

The study concluded that the cost of medical grade oxygen for the acute treatment of CH is not prohibitively expensive for patients or for insurance providers.

Does Alcohol Consumption Increase the Risk of Migraine Attack?

By September 11, 2017

Of the total migraine sufferers, alcohol was deemed a risk factor for 64% of them.

Cardiovascular Study Supports Safety of Novel Migraine Tx Erenumab

By September 11, 2017

Results showed that at the end of the 12-week trial participants in the Aimovig 140mg group had a reduction of 7 MMDs and the 70mg group had a reduction of 5.4 days, while the placebo group had a reduction of 2.7 days (P<0.001).

Device for Migraine Prevention and Treatment Gets FDA Clearance

By September 07, 2017

The non-invasive SpringTMS device is placed at the back of the patient's head where a forced magnetic pulse is delivered to treat an acute attack or to prevent a future migraine onset.

Migraine Drug Therapies Examined for Appropriateness

August 28, 2017

The study team found that of 2,860 Americans who visited the doctor for migraine relief, 15.2% were prescribed opioids.

Opioids Greatly Overused as Migraine Treatment, Study Finds

By August 17, 2017

For abortive medications, results showed that overall 18.9% of patients received all high quality abortive medication, 27% received some low quality abortive while 15.2% received opioids.

Investigational Migraine Drug Lasmiditan Effective in Phase 3 Study

By August 04, 2017

Results showed that a statistically significant number of those participants who received lasmiditan (in all doses) were pain-free at 2-hours post dosage compared to those who received placebo (the primary endpoint).

FDA Clears Non-Invasive Device to Treat Chronic Intractable Pain

By August 03, 2017

The Stimpod NMS460 includes a nerve-mapping pen-like probe which allows practitioners to locate nerves and evaluate the treatment progress.

CAM Use Among Migraine/Headache Sufferers Investigated

By August 02, 2017

The use of complementary and alternative medicine (CAM) specifically for the treatment of migraine and headache is "relatively low" in the U.S.

Teva Launches Generic Relpax

By August 02, 2017

Its agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.

Aimovig for Migraine Prophylaxis Under FDA Review

By July 21, 2017

If approved by the FDA, Aimovig will be the first monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor specifically intended for migraine prophylaxis.